Phase 1 including first-in-human clinical trials supports research teams testing biomarker-guided medicines or multi-modal treatments to establish early safety and efficacy for rare cancers.
Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines funds procurers’ innovations for better cancer care.
Innovative healthcare interventions for non-communicable diseases supports research consortia testing treatments in early-stage clinical trials to improve management of cardiovascular, metabolic, lung and kidney diseases.
Clinical trials for advancing innovative interventions for neurodegenerative diseases supports research teams testing therapies with complementary approaches to improve treatment of non-rare neurodegenerative diseases.
Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers supports cancer infrastructures to study diagnosis and treatment and improve access to care.
Leveraging functional genomics to reveal novel targets for cancer treatment supports research teams studying tumour heterogeneity to identify and validate more precise targets for cancer treatment.